We are live on ! Find out more
Stempoint Capital

Stempoint Capital Portfolio holdings

AUM $560M Turnover 64.34%
1-Year Est. Return 146.87%
This Fund
S&P 500
This Quarter Est. Return
+25.39%
1 Year Est. Return
+146.87%
3 Year Est. Return
+725.67%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$375M
AUM Growth
–
Cap. Flow
+$287M
Cap. Flow %
76.64%
Top 10 Hldgs %
39.49%
Holding
67
New
67
Increased
–
Reduced
–
Closed
–
Avg Time Held Equity + Options
0 years
Top 10 Avg Time Held Equity + Options
0 years
Top 20 Avg Time Held Equity + Options
0 years
Avg Time Held Equity only
0 years
Top 10 Avg Time Held Equity only
0 years
Top 20 Avg Time Held Equity only
0 years

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$21.1M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$16.8M
3
ACLX icon
Arcellx
ACLX
+$14.1M
4
IMVT icon
Immunovant
IMVT
+$11.8M
5
MRUS icon
Merus
MRUS
+$11.7M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 91.59%
2 Miscellaneous 8.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ROIV icon
1
Roivant Sciences
ROIV
$28B
$24.4M 6.5%
+2,169,116
New +$21.1M
2023 Q4
0 quarters
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$785M
$23.7M 6.31%
+1,094,494
New +$16.8M
2023 Q4
0 quarters
ACLX icon
3
DELISTED
Arcellx
ACLX
$17.4M 4.64%
+313,604
New +$14.1M
2023 Q4
0 quarters
MRUS icon
4
DELISTED
Merus
MRUS
$13.8M 3.68%
+501,806
New +$11.7M
2023 Q4
0 quarters
IMVT icon
5
Immunovant
IMVT
$6.57B
$13.6M 3.62%
+322,015
New +$11.8M
2023 Q4
0 quarters
FOLD icon
6
DELISTED
Amicus Therapeutics
FOLD
$12.2M 3.27%
+862,815
New +$9.8M
2023 Q4
0 quarters
PTGX icon
7
Protagonist Therapeutics
PTGX
$7.92B
$11.8M 3.14%
+513,681
New +$8.99M
2023 Q4
0 quarters
IMTX icon
8
Immatics
IMTX
$879M
$10.7M 2.87%
+1,020,214
New +$9.39M
2023 Q4
0 quarters
BBIO icon
9
BridgeBio Pharma
BBIO
$14.8B
$10.3M 2.74%
+253,948
New +$7.63M
2023 Q4
0 quarters
CABA icon
10
Cabaletta Bio
CABA
$202M
$10.2M 2.73%
+450,706
New +$7.58M
2023 Q4
0 quarters
MLTX icon
11
MoonLake Immunotherapeutics
MLTX
$942M
$10.1M 2.7%
+167,851
New +$8.65M
2023 Q4
0 quarters
ARGX icon
12
CALL
argenx
ARGX
$58.2B
$10.1M 2.69%
+26,484
New +$12.3M
2023 Q4
0 quarters
MRK icon
13
Merck
MRK
$330B
$9.7M 2.59%
+89,016
New +$9.24M
2023 Q4
0 quarters
JNJ icon
14
Johnson & Johnson
JNJ
$651B
$9.6M 2.55%
+61,011
New +$9.36M
2023 Q4
0 quarters
CRNX icon
15
DELISTED
Crinetics Pharmaceuticals
CRNX
$8.88M 2.37%
+249,575
New +$7.65M
2023 Q4
0 quarters
LLY icon
16
Eli Lilly
LLY
$1.2T
$8.78M 2.34%
+15,067
New +$8.79M
2023 Q4
0 quarters
VTGN icon
17
VistaGen Therapeutics
VTGN
$7.56M
$8.76M 2.34%
+1,790,182
New +$6.77M
2023 Q4
0 quarters
ARQT icon
18
Arcutis Biotherapeutics
ARQT
$3.33B
$8.38M 2.24%
+2,594,536
New +$7.05M
2023 Q4
0 quarters
SYRE icon
19
Spyre Therapeutics
SYRE
$8.88B
$8.15M 2.17%
+378,766
New +$5.22M
2023 Q4
0 quarters
TEVA icon
20
CALL
Teva Pharmaceutical Industries
TEVA
$45.8B
$7.32M 1.95%
+701,597
New +$6.55M
2023 Q4
0 quarters
IRON icon
21
Disc Medicine
IRON
$3.42B
$7.24M 1.93%
+125,429
New +$6.42M
2023 Q4
0 quarters
LNTH icon
22
Lantheus
LNTH
$6.68B
$6.75M 1.8%
+108,911
New +$7.38M
2023 Q4
0 quarters
LEGN icon
23
Legend Biotech
LEGN
$2.96B
$6.3M 1.68%
+104,650
New +$6.63M
2023 Q4
0 quarters
ATXS icon
24
DELISTED
Astria Therapeutics
ATXS
$6.16M 1.64%
+856,952
New +$4.74M
2023 Q4
0 quarters
INSM icon
25
Insmed
INSM
$31B
$5.38M 1.44%
+173,579
New +$4.5M
2023 Q4
0 quarters

Similar funds

Stempoint Capital's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for Stempoint Capital, which disclosed 67 positions worth $375M. Its ten largest holdings account for 39% of the portfolio.

Its largest position is Roivant Sciences: 2,169,116 shares worth $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, followed by Miscellaneous.

  • Stempoint Capital's largest Q4 2023 buy was Roivant Sciences: 2,169,116 shares worth $24.4M.
  • Stempoint Capital's ten largest holdings make up 39% of its $375M portfolio in Q4 2023.
  • Stempoint Capital disclosed 67 positions in Q4 2023, its first 13F filing on record.

Based on Stempoint Capital's 13F filing for Q4 2023, filed 13 Feb 2024.